Aminoglycoside Dosing Calculator
Calculate extended-interval aminoglycoside doses and monitoring from weight and CrCl. Enter values for instant results with step-by-step formulas.
Aminoglycoside Dosing Calculator
Calculate extended-interval aminoglycoside doses and monitoring parameters from patient weight, height, age, and creatinine clearance. Supports gentamicin, tobramycin, and amikacin.
Last updated: January 2026Reviewed by NovaCalculator Medical Editorial Team
Calculator
Adjust values & calculateFormula
Where DosePerKg is the mg/kg dose (7 for gentamicin/tobramycin, 15 for amikacin), DosingWeight is the lesser of actual or adjusted body weight, CrCl is creatinine clearance via Cockcroft-Gault, SCr is serum creatinine, and Ke is the elimination rate constant.
Last reviewed: January 2026
Worked Examples
Example 1: Extended-Interval Gentamicin Dosing
Example 2: Amikacin Dosing in Obese Patient
Background & Theory
The Aminoglycoside Dosing Calculator applies the following established principles and formulas. Health and medicine calculators are grounded in validated physiological measurement methods established through decades of clinical research. Body Mass Index, or BMI, is calculated by dividing weight in kilograms by height in meters squared (kg/m²), a formula originating from Adolphe Quetelet's 19th-century statistical work and later codified by the WHO into standard classifications: underweight below 18.5, normal weight 18.5 to 24.9, overweight 25 to 29.9, and obese at 30 and above. Basal Metabolic Rate quantifies the minimum energy required to sustain life at rest. The Mifflin-St Jeor equation, published in 1990 and widely regarded as the most accurate for most adults, calculates BMR as (10 × weight in kg) + (6.25 × height in cm) − (5 × age) ± sex adjustment. The older Harris-Benedict equations, revised in 1984 by Roza and Shizgal, remain in common use. Total Daily Energy Expenditure is derived by multiplying BMR by a physical activity factor ranging from 1.2 for sedentary individuals to 1.9 for extremely active ones, following the methodology validated by doubly labeled water studies. Body fat percentage can be estimated without laboratory equipment using the U.S. Navy circumference method, which uses neck, waist, and hip measurements, or via BMI-derived equations adjusted for age and sex. The Jackson-Pollock skinfold method offers higher precision with calipers. Blood pressure classification, according to the American College of Cardiology and the 2017 ACC/AHA guidelines, defines normal as below 120/80 mmHg, elevated as 120 to 129 systolic, and hypertension stage 1 as 130 to 139 systolic or 80 to 89 diastolic. Target heart rate zones for aerobic exercise are derived from maximum heart rate estimates, most commonly using the formula 220 minus age in years, with moderate-intensity training typically defined as 50 to 70 percent of maximum heart rate and vigorous intensity at 70 to 85 percent, consistent with CDC and American Heart Association guidelines. These thresholds guide safe and effective cardiovascular conditioning.
History
The history behind the Aminoglycoside Dosing Calculator traces back through the following developments. The history of health measurement stretches back to ancient Greece, where Hippocrates around 400 BCE laid the foundation for observational medicine by systematically recording patient symptoms, diet, and environment. His humoral theory, though scientifically superseded, established the principle that the body operates as an interconnected system subject to measurable imbalance. The transformation toward modern medicine accelerated in the 19th century. Louis Pasteur and Robert Koch developed germ theory in the 1860s and 1870s, identifying microorganisms as disease agents and enabling targeted interventions. Florence Nightingale, working during the Crimean War in the 1850s, introduced statistical analysis to nursing practice, demonstrating through data visualization that sanitation reduced mortality. Her work is foundational to evidence-based health measurement. The discovery of vitamins in the early 20th century, beginning with Casimir Funk's coinage of the term in 1912 and culminating in the isolation of vitamins A through K, created the field of nutritional science and gave rise to dietary reference intake frameworks. The World Health Organization, founded in 1948, subsequently established global standards for health metrics, disease classification through the International Classification of Diseases, and recommended daily allowances. The BMI as a clinical screening tool gained traction in the 1970s through Ancel Keys' large-scale epidemiological work, which validated Quetelet's index as a population-level obesity indicator. Through the 1980s and 1990s, the Framingham Heart Study produced landmark data linking cholesterol, blood pressure, and lifestyle factors to cardiovascular disease risk, directly shaping the numeric thresholds still used in health calculators. The evidence-based medicine movement, formalized by Gordon Guyatt and colleagues at McMaster University in the early 1990s, demanded that all health recommendations derive from systematically graded clinical evidence. The digital health era beginning in the 2000s brought these formulas to consumer devices, wearable sensors, and smartphone applications, expanding access to health self-monitoring on a global scale and enabling population-level data collection that continues to refine clinical reference ranges.
Frequently Asked Questions
Formula
Dose = DosePerKg x DosingWeight | CrCl = ((140-Age) x Weight) / (72 x SCr) [x 0.85 if female] | Ke = 0.00293 x CrCl + 0.014
Where DosePerKg is the mg/kg dose (7 for gentamicin/tobramycin, 15 for amikacin), DosingWeight is the lesser of actual or adjusted body weight, CrCl is creatinine clearance via Cockcroft-Gault, SCr is serum creatinine, and Ke is the elimination rate constant.
Worked Examples
Example 1: Extended-Interval Gentamicin Dosing
Problem: A 70 kg male, 170 cm tall, age 45, with serum creatinine 1.0 mg/dL needs gentamicin for a gram-negative infection.
Solution: IBW = 50 + 2.3 x ((170/2.54) - 60) = 50 + 2.3 x 6.93 = 65.9 kg\nActual wt (70) < 120% IBW (79.1), so use actual weight = 70 kg\nCrCl = ((140-45) x 70) / (72 x 1.0) = 92.4 mL/min\nVd = 0.25 x 70 = 17.5 L\nKe = 0.00293 x 92.4 + 0.014 = 0.285 hr-1\nDose = 7 mg/kg x 70 = 490 mg\nPredicted peak = 490/17.5 = 28.0 mcg/mL\nInterval = 24 hours (CrCl > 60)
Result: Dose: 490 mg IV q24h | Peak: 28.0 mcg/mL | CrCl: 92.4 mL/min
Example 2: Amikacin Dosing in Obese Patient
Problem: A 110 kg female, 160 cm tall, age 60, with serum creatinine 1.2 mg/dL needs amikacin.
Solution: IBW = 45.5 + 2.3 x ((160/2.54) - 60) = 45.5 + 2.3 x 2.99 = 52.4 kg\n120% IBW = 62.9 kg, actual (110) > 120% IBW, use ABW\nABW = 52.4 + 0.4 x (110 - 52.4) = 52.4 + 23.0 = 75.4 kg\nCrCl = ((140-60) x 75.4) / (72 x 1.2) x 0.85 = 59.4 mL/min\nVd = 0.25 x 75.4 = 18.9 L\nDose = 15 mg/kg x 75.4 = 1131 mg (round to 1100 mg)\nPredicted peak = 1100/18.9 = 58.2 mcg/mL
Result: Dose: 1100 mg IV q36h | ABW: 75.4 kg | CrCl: 59.4 mL/min
Frequently Asked Questions
What is extended-interval aminoglycoside dosing and why is it preferred?
Extended-interval dosing, also called once-daily or high-dose extended-interval administration, involves giving a larger dose less frequently, typically every 24 to 48 hours rather than every 8 hours. This approach takes advantage of the concentration-dependent killing properties and post-antibiotic effect of aminoglycosides. Studies have shown that extended-interval dosing produces equivalent or superior efficacy compared to traditional multiple daily dosing while reducing nephrotoxicity. The prolonged drug-free interval allows renal cortical cells to recover between doses, reducing accumulation and toxicity risk. Most clinical guidelines now recommend extended-interval dosing as the standard approach for most patients.
How is creatinine clearance used in aminoglycoside dosing calculations?
Creatinine clearance is a critical parameter because aminoglycosides are eliminated almost entirely by glomerular filtration in the kidneys. The Cockcroft-Gault equation estimates creatinine clearance using the patient age, weight, serum creatinine, and sex. Lower creatinine clearance indicates reduced renal function, which means the drug is eliminated more slowly, leading to higher trough levels and increased toxicity risk. Patients with creatinine clearance below 60 mL/min typically require extended dosing intervals of 36 to 48 hours. Critically ill patients may have rapidly changing renal function, requiring frequent reassessment and therapeutic drug monitoring to ensure safe and effective dosing.
What is the significance of peak and trough levels in aminoglycoside monitoring?
Peak levels represent the maximum drug concentration achieved after a dose and correlate with antimicrobial efficacy. For extended-interval gentamicin dosing, target peak levels are typically 15 to 25 mcg/mL. Trough levels represent the minimum concentration before the next dose and correlate with toxicity risk, particularly nephrotoxicity and ototoxicity. Target trough levels should generally be below 1 mcg/mL for extended-interval dosing. If trough levels remain elevated, the dosing interval should be extended. Monitoring both peak and trough levels helps clinicians optimize the balance between therapeutic efficacy and minimizing adverse effects throughout the treatment course.
How does body weight affect aminoglycoside dosing calculations?
Aminoglycosides distribute primarily into extracellular fluid, so dosing weight selection is critical for accurate calculations. For patients within 20 percent of their ideal body weight, actual body weight is typically used. For obese patients exceeding 120 percent of ideal body weight, adjusted body weight is calculated using the formula IBW plus 0.4 times the difference between actual and ideal weight. This correction factor of 0.4 accounts for the fact that aminoglycosides partially distribute into adipose tissue but not proportionally to total body weight. Using actual body weight in obese patients would result in excessive doses, while using ideal body weight alone would underdose them.
What are the main toxicities associated with aminoglycoside therapy?
The two primary toxicities are nephrotoxicity and ototoxicity. Nephrotoxicity occurs in approximately 10 to 25 percent of patients and manifests as a gradual rise in serum creatinine, typically reversible upon drug discontinuation. It results from drug accumulation in renal proximal tubular cells. Ototoxicity affects both vestibular and cochlear function, potentially causing dizziness, vertigo, hearing loss, or tinnitus. Unlike nephrotoxicity, ototoxicity may be irreversible. Risk factors for both toxicities include prolonged therapy beyond 7 days, elevated trough concentrations, concurrent use of other nephrotoxic drugs, dehydration, and advanced age. Extended-interval dosing significantly reduces these risks compared to traditional dosing regimens.
How should aminoglycoside dosing be adjusted in patients with renal impairment?
Renal impairment is the most important factor requiring dose adjustment because aminoglycosides are cleared almost exclusively by the kidneys. For patients with creatinine clearance between 40 and 60 mL/min, the standard dose is maintained but the interval is extended to 36 hours. For clearance between 20 and 40 mL/min, intervals of 48 hours are typically recommended. For patients with clearance below 20 mL/min or on hemodialysis, individual pharmacokinetic calculations and close therapeutic drug monitoring are essential. In dialysis patients, aminoglycosides are administered after dialysis sessions since hemodialysis removes a significant proportion of the drug. Continuous renal replacement therapy requires specialized dosing protocols.
References
Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy